Last mentioned: 3h ago
Exclusive License Agreement
Dimerix announces licensing deal with Everest Medicines for Asian commercialization.
Eighth DSMB Safety Review
Independent committee finds no safety concerns in ongoing trial.
Statistical Power Confirmation
External blinded review confirms the trial retains over 90% statistical power for the primary endpoint.
Positive Interim Results
Dimerix reports DMX-200 performing better than placebo in reducing proteinuria in the ACTION3 adult cohort.
Biotech Dimerix secures a regional licensing deal with Everest Medicines, retaining Western rights for its Phase 3 FSGS candidate. Trial remains on track with strong interim efficacy and clean safety, plus a high probability of success.
This page surfaces every story mentioning DMX-200 across our biotech coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running biotech beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where DMX-200 was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |